红景天对X射线照射大鼠外周血及抗氧化能力的影响

目的探讨长白山红景天有效成分对X射线照射大鼠外周血及抗氧化能力的影响。方法建立X射线辐射大鼠模型,照射前用长白山红景天苷进行干预,观察各组大鼠白细胞(WBC)、红细胞(RBC)、谷胱甘肽过氧化物酶(GSH-Px)及超氧化物歧化酶(SOD)的变化。结果与单纯X射线照射组相比,照射前服用红景天药物的大鼠外周血WBC、RBC数明显上升(P<0.05),血清GSH-Px和SOD活力值显著升高(P<0.05),且高剂量组的活力值升高的更为明显。结论红景天苷有一定的抗辐射作用。     

抗人胃腺癌单克隆抗体的制备及其在临床应用中的探讨

本文应用杂交瘤技术制备出4株抗胃腺癌细胞株SGC-7901单克隆抗体,4株单克隆抗体的相应抗原与CEA、HLA、ABO抗原无关。免疫酶组织化学染色法证明,相应抗原位于细胞膜及细胞浆,因癌腺腔内也可见到阳性染色,说明相应抗原是分泌性抗原。临床应用结果表明,4株单克隆抗体与胃癌组织有较强的特异性,值得进一步推广应用。     

维生素D3—β—环糊精包合物的制备及鉴定

探讨优化维生素Ｄ３－β－环糊精包合物的制备方法并鉴定其形成。方法：以维生素Ｄ３利用率和收率为综合指标研究了溶液法、胶体磨法、超声波法和研磨法等制备维生素Ｄ３－β－环糊精包合物的方法。结果：当β－环糊精和维生素Ｄ３以３：１摩尔量投料时维生素Ｄ３利用率和收率最高。     

经支气管镜大容量灌洗治疗支气管扩张症并感染患者的前瞻性研究

目的评价经支气管镜大容量灌洗治疗支气管扩张症并感染的安全性和有效性。方法采用随机、对照的临床试验设计,对2009年8月至2014年1月收治的支气管扩张症并感染患者进行研究。入选病例在合理内科药物治疗前提下,65例患者随机分为大容量灌洗组（A组,n=21）、小容量灌洗组（B组,n=22）及对照组（C组,n=22）。灌洗组均接受一次治疗,大容量灌洗组灌洗量为500~2 000 m L,小容量灌洗组灌洗量为100~200 m L。观察记录患者的一般情况,记录并比较治疗前、后各组简化的临床肺部感染评分（CPIS）、C反应蛋白（CRP）水平、抗生素使用时间、住院时间及治疗有效率。结果 A组灌洗量为（1 250.0±403.3）m L,B组灌洗量为（141.0±41.2）m L。A组的住院时间和抗生素使用时间分别为（8.4±1.0）d和（7.9±1.1）d,短于B组[（13.5±1.6）d、（11.6±2.4）d]和对照组[（15.3±3.2）d、（13.3±2.6）d]（P〈0.05）;总有效率为95.23%,高于B组（81.82%）和C组（68.19%）;第7 d A组的CPIS评分为（1.9±1.4）分,低于B组[（2.7±0.8）分]和C组[（3.7±0.9）分]（P〈0.05）;A组CRP下降更为显著,差异均有统计学意义（P〈0.05）。A组和B组不良反应分别为一过性低氧血症（23.81%、9.09%）、窦性心动过速（100%、68.18%）、气道黏膜损伤（38.09%、13.64%）、血压升高（19.05%、13.64%）。结论经支气管镜选择性大容量支气管灌洗治疗支气管扩张并感染安全、有效,值得临床推广。     

二尖瓣位机械瓣梗阻的彩色多普勒评价

目的评价彩色多普勒超声在诊断二尖瓣位机械瓣(单叶碟瓣)梗阻的价值。方法对比二尖瓣位机械瓣梗阻12例的彩色多普勒超声结果与手术所见。结果左心长轴切面和心尖四腔切面可较清晰地显示二尖瓣位机械瓣梗阻患者的瓣叶活动显著受限,瓣叶开放角度平均10°(0°-25°),彩色血流束呈单束或双束狭窄的边缘血流束,无瓣周漏及中度以上的瓣关闭不全,最大跨瓣血流速度及压差无显著改变:术中见12例瓣叶均被“卡”在近关闭状态位,开放角度小于300°,瓣周纤维肉芽组织增生伴血栓形成,瓣口狭小(0-0．5mm),其中4例瓣口及瓣周完全被血栓块“封堵”。结论彩色多普勒超声心动图显示机械瓣梗阻特征为瓣叶开放角度和幅度显著减小,瓣口呈边缘性狭窄血流束,与手术所见一致,但瓣口血流速度及压差指数等特异改变在彩色多普勒超声心动图不明显;虽然彩色多普勒超声心动图对异常增生组织和血栓的显示不清晰,但仍不失为诊断二尖瓣位机械瓣梗阻的简便有效的手段。     

Skeletal myoblast based delivery of angiogenic growth factors: a comparison between angiopoietin-1 and VEGF gene delivery for therapeutic angiogenesis in the heart

Introduction Extensive cell death and an associated myocardial dys- function are the common features of chronic heart disease. Given the inadequate ability of the human heart to regenerate, a more recent approach to counter the remodel- ing process is to compensate for the loss of functioning cardiomyocyte number through stem cell transplantation with angiomyogenic potential.1,2 The novel approach of heart cell therapy is to repopulate the scar tissue with myogenic cells that may be functional…     

Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction

Background Many basic and clinical studies have proved that anisodamine can produce significant effect on relieving microvascular spasm, improving and dredging the coronary microcirculation. It may be beneficial to the improvement of slow-reflow phenomenon (SRP) following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). So we investigated the effect of intracoronary administration of anisodamine on SRP of infarct related artery (IRA) following primary PCI in patients with ST segment elevated acute myocardial infarction (STEAMI). Methods Twenty-one patients with SRP from a total of 148 STEAMI patients accepted primary PCI were enrolled into this study from September 2004 to December 2005. When SRP happened, nitroglycerin (200 &micro;g) was “bolus” injected firstly into IRA to exclude the spasm of epicardial artery and identify SRP as well as a baseline and self-control agent following PCI. Ten minutes later, 1000 &micro;g of anisodamine was injected into IRA with SRP at 200 &micro;g/s, while the coronary angiography (CAG) was taken before and at 1st, 3rd and 10th minute after administration of nitroglycerin or anisodamine, respectively. The corrected TIMI frame count (cTFC), TIMI myocardial perfusion grade (TMPG) and the diameter of IRA were calculated and analyzed by Gibson’s TIMI frame count method using quantitative computer angiography (QCA) system to evaluate the influence of anisodamine on coronary flow and vessel lumen. In the meantime the invasive hemodynamic parameters of intracoronary and systemic artery (systolic, diastolic and mean pressure) and electrocardiogram (ECG) were measured and monitored. The changes of ventricular performance parameters and the adverse reaction were evaluated and followed-up at 1 month post-PCI. Results No significant changes in cTFCs and TMPGs were found at 1st, 3rd and 10th minute after intracoronary administration of nitroglycerin as compared with the baseline control (P＞0.05). cTFCs were decreased by 58.3%, 56.2%, and 54.6%, respectively (P&lt;0.001), and TMPGs were increased from 1.13±0.21 grade to 2.03±0.32, 2.65±0.45 and 2.51±0.57 grades (P&lt;0.05) at 1st, 3rd and 10th minute after intracoronary administration of anisodamine as compared with those after intracoronary administration of nitroglycerine, respectively. The average coronary blood flow of TIMI grade was improved from 1.76±0.43 to 2.71±0.46 (P&lt;0.05) while the diameter of middle segment in re-patented coronary artery was slightly increased from (3.20±0.40) mm to (3.40±0.50) mm at the 3rd minute after intracoronary administration of anisodamine (P＞0.05) as compared with those of nitroglycerine control. The systolic, diastolic and mean pressures of intracoronary artery after intracoronary administration of anisodamine increased from 115 to 123, 75 to 84, 88 to 95 mmHg (P&lt;0.05), respectively, along with the rise of heart rate from 68 to 84 beats per minute (P&lt;0.05). There were no significant changes in intervals of PR, QT and QRS (P＞0.05) and no any severe fast arrhythmia after intracoronary administration of anisodamine. The ventricular performance parameters were significantly improved and no major adverse cardiovascular events (MACE) were found during follow-up at 1 month post-PCI. Conclusions Intracoronary administration of 1000 &micro;g anisodamine is effictive in reversing SRP following PCI in STEAMI patients, especially it is suitable for SRP patients with bradycardia or hypotension.     

芪参益气滴丸与西药联合治疗冠心病心绞痛气虚血瘀证患者临床疗效及对患者心功能的影响

目的：探讨芪参益气滴丸与西药联合治疗冠心病心绞痛气虚血瘀证患者临床疗效及对患者心功能的影响。方法将67例中医辩证分型为气虚血瘀证的冠心病心绞痛患者根据就诊先后顺序将患者分为观察组和对照组,对照组患者给予常规西药治疗,观察组患者给予芪参益气滴丸与西药联合治疗,两组均连续治疗2个月后观察心绞痛疗效和治疗前后心功能指标左室射血分数（ LVEF）、心输出量（ CO）、加速指数（ ACI）、胸腔液体含量（ TFC）和体血管阻力（ SVR）变化。结果观察组心绞痛总有效率为79.41％,显著高于对照组的63.64％,差异有统计学意义（P＜0.05）;两组治疗后LVEF、CO、ACI较治疗前显著升高,TFC、SVR显著降低,差异均有统计学意义（ P＜0.05）;观察组治疗后LVEF、CO、ACI显著高于对照组治疗后,TFC显著低于对照组治疗后,差异均有统计学意义（ P＜0.05）。结论芪参益气滴丸与西药联合治疗冠心病心绞痛气虚血瘀证患者心绞痛疗效确切,且能显著改善患者心功能,具有重要的临床意义。     

SHP-2抑制剂PHPS1对动脉粥样硬化斑块作用及其机制的研究

目的 探讨蛋白酪氨酸磷酸酶SHP-2抑制剂PHPS1对ApoE基因敲除小鼠动脉粥样硬化斑块易损性的作用及其机理,为研究动脉粥样硬化提供新思路.方法 16只8周龄ApoE-/-小鼠随机分为对照组和PHPS 1组,给予西方膳食饲料16周,构建易损AS模型.取主动脉根部经福尔马林固定后制成切片,行Movat、天狼星红等染色法...     

Construction of adeno-associated virus coexpression system for human angiopoietin-1 and VEGF gene

Background Ischemic disease is one of the leading causes of death in the world. In order to further study gene therapy for ischemic disease, we constructed a recombinant plasmid for co-expression of human angiopoietin-1 and vascular endothelial growth factor 165 (VEGF165) gene in adeno-associated virus (AAV) gene delivery system.Methods Human angiopoietin 1 and VEGF165 gene were obtained using PCR. The upstream of angiopoietin 1 contained restriction enzyme site Hind Ⅲ,contained restriction enzyme site BamH Ⅰ. The upstreamand the downstream of angiopoietin 1 of VEGF165 contained restriction enzyme site Bgl Ⅱ, and the downstream of VEGF165 contained restriction enzyme site BamH Ⅰ, Using the multiple cloning sites (MCS) in plasmid pZero such as BamH Ⅰ , Bgl Ⅱ, Hind Ⅲ, Not Ⅰ , Xho Ⅰ ,Xba Ⅰ , Sal Ⅰ , BspH Ⅰ , Ksp Ⅰ and the corresponding MCS in plasmid pAAV-MCS, angiopoietin 1 and VEGF165 gene were subcloned into pAAV-MCS.Results DNA sequencing revealed that the PCR- amplified angiopoietin 1 and VEGF165 were consistent with NCBI Gene Bank. The recombinant plasmid was identified using PCR and digestion,which proved to be consistent with our hypothesis. In recombinant plasmid, angiopoietinl and VEGF possessed a CMV promoter and polyA terminator system respectively, thus assuring co-expression of the two genes.Conclusion Successful construction of AAV co-expression system for human angiopoietin 1 and VEGF165 gene will provide the foundation for gene therapy to cure severe ischemic disease.